Insulet
Insulet Corporation, commonly known for its innovative Omnipod® Insulin Management System, is a leading player in the diabetes care industry. Headquartered in the United States, Insulet operates primarily in North America and Europe, focusing on developing advanced insulin delivery solutions. Founded in 2000, the company has achieved significant milestones, including the launch of its tubeless insulin pump, which revolutionised diabetes management for many patients. Insulet's core product, the Omnipod, stands out due to its unique design that offers a wireless, waterproof, and discreet insulin delivery system. This innovative approach has positioned Insulet as a market leader, recognised for enhancing the quality of life for individuals with diabetes. With a commitment to continuous improvement and patient-centric solutions, Insulet remains at the forefront of diabetes technology, driving advancements that empower users to manage their condition effectively.
DitchCarbon Score
How does Insulet's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Insulet's score of 26 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Insulet's reported carbon emissions
In 2023, Insulet Corporation reported total carbon emissions of approximately 5,300,000 kg CO2e, comprising about 1,316,000 kg CO2e from Scope 1 and approximately 3,977,000 kg CO2e from Scope 2 emissions. This marks a reduction from 2022, where emissions were about 5,500,000 kg CO2e, with Scope 1 emissions at approximately 1,455,000 kg CO2e and Scope 2 emissions at around 4,574,000 kg CO2e. Over the years, Insulet has demonstrated a commitment to reducing its carbon footprint, with a notable decrease in emissions from 2020, when total emissions were about 4,440,000 kg CO2e (1,709,000 kg CO2e from Scope 1 and 3,034,000 kg CO2e from Scope 2). Despite these reductions, Insulet has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on sustainability as part of its operational strategy, reflecting a growing awareness of climate impact within the medical device industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 1,709,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 3,761,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Insulet is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
